Quote:

---

“I am hoping this is the beginning of the end to having anti-amyloid medications FDA-approved for the treatment of Alzheimer’s dementia. Clinical neurologists continue to not use this family of medications as they have not significantly improved patients’ memory loss in the drug trials and have caused severe cerebral edema and intracranial bleeding,” Dr. Segil said.

---

Aduhelm had very few prescriptions and Biogen decided to push their other Alzheimer's drug Leqembi instead. Guaranteed that Leqembi will also be a commercial failure. Marketing and distribution costs will far outweigh any revenue. Why would doctors want to induce greater suffering with little to no benefit.